Trade OXFORD BIOMEDICA PLC ORD 50P - OXB CFD
Add to favourite- Summary
- Historical Data
Spread | 0.178 | ||||||||
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02461% | ||||||||
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.002692% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | GBP | ||||||||
Margin | 5.00% | ||||||||
Stock exchange | United Kingdom of Great Britain and Northern Ireland | ||||||||
Commission on trade | 0% |
Prev. Close | 3.781 |
Open | 3.796 |
1-Year Change | 26.15% |
Day's Range | 3.736 - 3.866 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Oct 11, 2024 | 3.781 | -0.015 | -0.40% | 3.796 | 3.866 | 3.736 |
Oct 10, 2024 | 3.781 | -0.025 | -0.66% | 3.806 | 3.856 | 3.736 |
Oct 9, 2024 | 3.766 | -0.055 | -1.44% | 3.821 | 3.836 | 3.761 |
Oct 8, 2024 | 3.796 | 0.060 | 1.61% | 3.736 | 3.846 | 3.736 |
Oct 7, 2024 | 3.816 | 0.030 | 0.79% | 3.786 | 3.886 | 3.726 |
Oct 4, 2024 | 3.776 | 0.030 | 0.80% | 3.746 | 3.901 | 3.691 |
Oct 3, 2024 | 3.776 | 0.065 | 1.75% | 3.711 | 3.816 | 3.706 |
Oct 2, 2024 | 3.776 | 0.135 | 3.71% | 3.641 | 3.791 | 3.641 |
Oct 1, 2024 | 3.721 | -0.025 | -0.67% | 3.746 | 3.796 | 3.676 |
Sep 30, 2024 | 3.656 | -0.060 | -1.61% | 3.716 | 3.841 | 3.656 |
Sep 27, 2024 | 3.796 | 0.015 | 0.40% | 3.781 | 3.866 | 3.696 |
Sep 26, 2024 | 3.711 | 0.115 | 3.20% | 3.596 | 3.776 | 3.596 |
Sep 25, 2024 | 3.696 | 0.030 | 0.82% | 3.666 | 3.741 | 3.586 |
Sep 24, 2024 | 3.661 | 0.045 | 1.24% | 3.616 | 3.766 | 3.546 |
Sep 23, 2024 | 3.596 | 0.200 | 5.89% | 3.396 | 3.596 | 3.396 |
Sep 20, 2024 | 3.431 | 0.040 | 1.18% | 3.391 | 3.501 | 3.366 |
Sep 19, 2024 | 3.436 | 0.140 | 4.25% | 3.296 | 3.501 | 3.266 |
Sep 18, 2024 | 3.311 | -0.005 | -0.15% | 3.316 | 3.401 | 3.296 |
Sep 17, 2024 | 3.336 | -0.020 | -0.60% | 3.356 | 3.481 | 3.296 |
Sep 16, 2024 | 3.496 | 0.185 | 5.59% | 3.311 | 3.531 | 3.281 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Oxford BioMedica plc Company profile
About Oxford BioMedica plc
Oxford BioMedica Plc is a United Kingdom-based gene and cell therapy company. The Company and its subsidiaries have developed lentiviral vector delivery system, LentiVector platform, which the Company leverages to develop in vivo and ex vivo products both in-house and with partners. Its LentiVector delivery platform has created a portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, central nervous system (CNS) disorders and liver diseases. The Company's product pipeline includes OXB-302, OXB-203, OXB-204 and OXB-103 and OXB-401. The Company has also developed partnership with various pharmaceutical companies to develop potential gene and cell therapy products. Its partnered products include AXO-LENTI-PD, SAR 422459 and SAR421869.
Financial summary
BRIEF: For the six months ended 30 June 2021, Oxford BioMedica plc revenues increased from £34M to £81.3M. Net income totaled £18.1M vs. loss of £6.7M. Revenues reflect Europe segment increase from £19M to £70.3M. Net Income reflects Platform segment income totaling £24.4M vs. loss of £3.1M. Basic Earnings per Share excluding Extraordinary Items increased from -£0.09 to £0.22.
Equity composition
10/2003, Rights Issue, 27 new shs for every 50 shs held @ GBP 0.17 (Fct:1.54). 03/2001, Rights Issue, 1 new share for every 9 shs held @ GBP 0.55 (Fct:1.111111). 03/1998, Rights Issue, 1 new share for every 4 shs held @ GBP 0.10 (Fct:1.076). 05/2014, Priority Issue, 1 new shares for every 5 shares held @ GBp 2 (Factor:1).
Industry: | Bio Therapeutic Drugs |
Windrush Court
Transport Way
OXFORD
OXFORDSHIRE OX4 6LT
GB
News
S&P 500 expected to deliver modest earnings growth in Q3
Earnings growth across the S&P 500 is expected to be modest in Q3, with a projected 4.2% increase in EPS, down from 7.8% in the previous quarter. Information technology, health care, and communication services are poised to drive growth, particularly IT with a forecasted 15% year-over-year EPS increase.
12:40, 11 October 2024US Core CPI tipped to remain unchanged in September
US inflation expectations are steady, with core CPI projected to remain at 3.2% for September while headline inflation moderates to its lowest level since February 2021. Despite the US Federal Reserve delivering a 50 basis point interest rate cut in September, stronger-than-expected job market data has raised concerns about sustained economic demand and inflation pressures.
07:10, 9 October 2024RBNZ expected to deliver “jumbo” rate cut
The Reserve Bank of New Zealand is set to cut interest rates during its upcoming meeting, with expectations of either a 25 or 50 basis point reduction. This move follows a 25 basis point cut in August as the RBNZ responded to the country’s recessionary conditions and inflation concerns.
08:48, 8 October 2024September Non-Farm Payrolls eases fears of US economic slowdown
Markets are reacting with a US Dollar surge and a potential trend reversal, highlighting the impact of robust economic activity outside of monetary policy influences.
07:44, 8 October 2024Gold's recent story
Last week, we explored the key price drivers of gold, and how they impacted the price of the precious metal this year and last. Now, we’ll bring these factors to life in a chart, showing you ten instances the gold price responded to critical fundamental events, including central bank policies, global economic data, and geopolitical events.
15:36, 7 October 2024September US Non-Farm Payrolls Preview
Kyle Rodda, Senior Market Analyst at Capital.com, previews the US Non-Farm Payrolls report for September. The article discusses market expectations of a stable labor market with 150,000 new jobs, an unchanged unemployment rate of 4.2%, and steady annual wage growth at 3.8%. It also highlights potential rate cuts by the Federal Reserve, revisions to past payroll data, and the reaction of various markets such as the US Dollar, S&P 500, and gold.
07:59, 2 October 2024Market of the Month - Gold, an overview
In 2024, gold has been on an upward trajectory, hitting high after high as global markets face ongoing challenges. This precious metal, long seen as a safe haven, has been proving its worth, drawing attention from traders around the world as its bullish surge continues.
06:00, 30 September 2024People also watch
Still looking for a broker you can trust?
Join the 650,000+ traders worldwide that chose to trade with Capital.com